May 19-23, 2018
Baltimore Convention Center
Baltimore, MD, USA
Visit the Sciformix Booth: #809
ISPOR is recognized globally as the leading educational and scientific organization for health economics and outcomes research (HEOR) and its use in health care decisions. If you want to meet people in the health economics and outcomes research (HEOR) field, discuss the latest trends, and learn from the experts, attend ISPOR Baltimore!
The ISPOR International Meeting features three thought-provoking plenary sessions and more than 2,100 presentations in the form of workshops, issue panels, forums, symposia, and podium and poster presentations on innovative research methods, health policy development using outcomes research, patient preferences, real-world data, and clinical-, economic-, and patient-reported outcomes.
In addition, ISPOR offers a series of pre-Meeting short (training) courses on trending topics in the HEOR field. ISPOR short courses range from introductory to advanced and are taught by leading experts in the field, with many incorporating group exercises and hands-on training opportunities!
Please stop by and ask our SME’s about our Posters at ISPOR:
- BLOCKCHAIN ENABLED REAL WORLD EVIDENCE (RWE): A FUTURE PERSPECTIVE
This poster reviews the current and future applications of blockchain in RWE. Blockchain technology enables streamlining, storing and sharing medical information in a secure manner among stakeholders like insurers, providers, patients, manufacturers among others. Linking and sharing real world data (RWD) like electronic health records (EHR), real time internet of things (IoT) network data via blockchain can be utilized for executing smart contracts.
- EXPLORING USE OF REAL WORLD EVIDENCE (RWE) IN US VALUE ASSESSMENT FRAMEWORKS (VAFS)
This poster examines how Real World Evidence (RWE) is currently incorporated in US Value Assessment Frameworks (VAFs).
- HEALTH TECHNOLOGY AND REGULATORY ASSESSMENT OF ADHERENCE AND IMPROVED OUTCOMES FOR SECOND GENERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA
This poster reviews the HTA and regulatory bodies’ perspective on use of adherence evidence for second-generation antipsychotics (SGAs) in schizophrenia, and identify assessment gaps in decision-making.